Highline Wealth Partners’s Biogen BIIB Stock Holding History

Highline Wealth Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.3K	Buy	219 +62	+39%	+$11.9K	0.01%	239
2026 Q1	$28.8K	Buy	+157	New	+$28.9K	0.01%	240

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Highline Wealth Partners's BIIB Position: Q2 2026 in Review

Highline Wealth Partners increased its Biogen (BIIB) stake by 39% in Q2 2026, buying an estimated $11.9K and bringing the position to 219 shares worth $47.3K. The position accounts for 0.01% of the portfolio, ranked #239.

Highline Wealth Partners first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Highline Wealth Partners held 219 shares of Biogen worth $47.3K as of Q2 2026.
Highline Wealth Partners bought 62 Biogen shares in Q2 2026, an estimated $11.9K.
Biogen made up 0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #239 holding.
Highline Wealth Partners first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.